Given the heterogeneity in GBM tumor cells, focused ultrasound presents an innovative strategy to temporarily disrupt the BBB, enhancing targeted drug delivery of GLUT1 inhibitors. The gene discussed is SLC2A1; the disease is glioblastoma.